CRISPR Therapeutics reports Q1 2026 results, highlights CASGEVY sales and pipeline progress

CRISPR Therapeutics announced its Q1 2026 financial results, reporting $43 million revenue from CASGEVY, its gene-editing therapy for sickle cell disease and beta thalassemia. The company expanded clinical programs, including autoimmune and liver-directed gene editing therapies, and advanced multiple candidates toward clinical trials. With a strong cash position of $2.44 billion and ongoing collaborations, CRISPR expects 2026 to be a pivotal year with several upcoming milestones and regulatory updates. Net loss narrowed to $122.9 million from $136 million a year earlier, reflecting operational efficiencies and increased revenue share from CASGEVY sales.